As chronic lymphocytic leukemia (CLL) is characterized by overexpression of pro-survival BCL2, compounds that mimic its physiological antagonists, the BH3-only proteins, may have a role in treatment of this disease. ABT-737 is a BH3 mimetic compound that selectively targets BCL2 and BCLX L . In the present work, we report that ABT-737 is highly effective (LC 50 o50 nM) as a single agent against most (21/30) primary CLL samples, but that a sizable minority is relatively insensitive. In vitro sensitivity to ABT-737 could not be simply predicted by the patients' clinical features, including response to prior therapy or known prognostic markers (CD38 expression, 17p deletion), or the relative expression of BCL2 family proteins (BCL2, MCL1, BAX, BIM). Strikingly, co-incubation with cytotoxic agents (dexamethasone, etoposide, fludarabine, doxorubicin) sensitized most CLL samples to ABT-737, but this could not be predicted by responses to either ABT-737 or the cytotoxic agent alone. Of 17 samples least sensitive to ABT-737, 13 were sensitized by co-treatment with at least one cytotoxic agent. These data indicate that combination of ABT-737 with a second anti-leukemic agent would improve response rates and suggest a potential role for combination therapies that include BH3 mimetics for the treatment of this disease.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western societies 1 and is distinguished by the expansion of a monoclonal CD5 þ CD23 þ B lymphocyte population. These cells accumulate because of dysregulated production and inappropriately prolonged survival because of impairment of apoptosis. 2, 3 Significant heterogeneity exists in the natural history of the disease and the genetic events that underpin CLL. 4 Reflecting this diversity, prognosis is variable. Although clinical staging systems remain the standard prognostic tool in practice, 1 additional prognostic markers have been identified, in particular the mutational status of the rearranged immunoglobulin heavy-chain variable region heavy gene (IgVH), 5 cytogenetic abnormalities, 6 expression of the 70 kD zeta-associated protein-70 7, 8 and the CD38 antigen. 9 In contrast to this heterogeneity, the overexpression of BCL2 is almost universal and largely accounts for the block in apoptosis. BCL2 is a key regulator of the intrinsic (or mitochondrial) apoptosis pathway. 10 Excessive levels of BCL2 promote inappropriate survival leading to tumor formation and chemoresistance. 11 In most cases of CLL, the leukemic population has elevated BCL2 mRNA and BCL2 protein levels in the absence of gene rearrangements, such as the t(14;18) chromosomal translocation that deregulates BCL2 in follicular lymphoma. 12, 13 In many cases, this overexpression may be explained by the loss or downregulation of the microRNA-15a and microRNA-16-1 located on 13q14.3. 14, 15 Given its central role in the biology of the disease, BCL2 inhibition is an attractive target for treatment of CLL. A number of agents designed to induce killing of the leukemic cells by inhibiting BCL2 and related members of the BCL2 protein family with similar pro-survival function have been reported, some of which are in clinical trials. These agents include the BCL2 anti-sense oligonucleotide Oblimersen 16, 17 and small organic compounds such as HA14-1, 18, 19 Obatoclax, 20 Apogossypol 21, 22 and ABT-737 23 that directly inhibit the action of the pro-survival proteins.
ABT-737 is designed to mimic the natural antagonists of the pro-survival BCL2 proteins, the BH3-only proteins. 24 This BH3 mimetic compound binds with high affinity to a subset of the pro-survival proteins (BCL2, BCLX L , BCL-W), but not to MCL1 or A1. 23, 25 It specifically induces apoptosis of some tumor cell lines and primary clinical samples, 23, 26, 27 usually when MCL1 is absent or inactivated 25, 28, 29 as most, if not all, pro-survival BCL2 proteins have to be inactivated for efficient cell death to proceed. 30 Other studies 26, 27 report that sensitivity of CLL cells to ABT-737 in vitro does not strictly correlate with MCL1 levels.
The aim of our study was to better define the spectrum of sensitivity of CLL cells to ABT-737, and to evaluate potential predictors of this sensitivity. In particular, the in vitro sensitivity of chemo-refractory or poor prognosis disease was examined, as well as the potential for ABT-737 to synergize with standard cytotoxic drugs to induce cell killing. Our results are informative for the clinical utility of the BH3 mimetic compounds especially ABT-263, 31 a compound in the same class as ABT-737, which is in Phase I clinical trials for a number of indications including CLL. 32 F-Ara-A, the active metabolite of fludarabine, 0-10 mM.
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Cytotoxicity assays
Cells were incubated with various concentrations of ABT-737 and/ or the chemotherapy agents dexamethasone, etoposide, doxorubicin or F-ara-A for 24 h. Cell viability was quantified by flow cytometric analysis of cells that excluded 5 mg/ml propidium iodide detected using a FACScan analyser (Becton Dickinson, Franklin Lakes, NJ, USA). Results were normalized to the viability of cells left untreated for 24 h, and are reported as the means±s.d. of three independent experiments performed on the same sample. The lethal concentration 50 (LC 50 ) is defined as the concentration of the drug that reduces cell viability by 50%.
Calculation of synergy
The predicted additive effect of two compounds was calculated using the Bliss method of fractional independence. 35 The ratio of observed to predicted effect is represented as the combination index (CI), with an index of 1 indicating an additive effect. Synergy is represented as a CIo1, whereas for an antagonistic combination the combination index is 41.
Western blot analysis Cell lysates. Cells were counted, washed once in ice-cold human tonicity phosphate buffered saline, lysed in lysis buffer (20 mM Tris-HCl pH 7.4, 135 mM NaCl 2 , 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 2 mM NaV 3 O 4 , 50 mM NaF, 1 mg/ml pepstatin, 1 mg/ml aprotinin and 1 mg/ml leupeptin) at concentrations of 5, 3.5 and 2 million cells per 10 ml, then stored at À80 1C.
Purified recombinant proteins. Human BCL2 DC22, 36 BCLX L DC24, 30 BCL-W C29S A128E DC29, 37 MCL1 DN170 DC23 38 and BAX DC21 39 were expressed and purified as described earlier. 30, 39 Human BIM S DC27 was cloned into the pETDuet-1 vector (Novagen, Darmstadt, Germany); the protein was N-terminally HIS 6 tagged and purified on a nickel affinity column followed by size exclusion chromatography. The protein concentrations were calculated based on their absorbance at 280 nM. 40 Western blot and protein quantification. Protein lysates from patient samples, along with five serial dilutions of purified recombinant protein per gel (NuPAGE Bis-Tris pre-cast gels; Invitrogen, Carlsbad, CA, USA), were separated by SDS-PAGE gel electrophoresis, before either wet (Towbin transfer buffer: 12 mM Tris-HCl, 96 mM glycine, 20% methanol) or dry (iBlot dry blotting system; Invitrogen) transfer to nitrocellulose membranes (Hybond-C; GE Healthcare, Little Chalfont, UK). After overnight blocking (Odyssey Blocking Buffer; LI-COR Biosciences, Lincoln, NE, USA), membranes were incubated with primary antibody ( After each incubation step, membranes were washed in PBS containing 0.1% Tween-20. Membranes were scanned and analyzed using the Odyssey Infrared Imaging System (LI-COR Biosciences). Using the signal intensities from the protein standards, a reference curve was plotted and the quantification of the protein of interest in the clinical samples determined by reading off the reference curve using Odyssey software v2.1. Protein quantity was normalized for loading using the integrated intensity of control (actin and/or GAPDH) bands.
Chromosomal and FISH analysis
Fluoroscent in situ hybridization (FISH) analysis was undertaken to detect for the loss of p53 locus on 17p. 43 Cytogenetic suspensions stored in Carnoy's fixative at À80 1C were used for FISH analysis using TP53 locus-specific probe (LSI p53 (17p13.1) Spectrum Orange, Vysis, Downers Grove, IL, USA) according to the manufacturer's instructions. Fresh slides were prepared from cytogenetic suspensions and incubated for 20 min on a 100 1C hotplate. Probe was added to slide, co-denatured at 73 1C for 2 min and hydridized overnight at 37 1C. Slides were washed according to the Vysis rapid wash protocol, air dried and mounted with 4'-6-Diamidino-2-phenylindole (DAPI)/antifade. Fluorescent signals were visualized and analyzed using an Axioplan 2 (Zeiss, Jena, Germany). A minimum of 200 interphase cells were scored for signal copy number.
Flow cytometry
Cells were prepared for analysis with using directly conjugated monoclonal antibodies in a lyse no-wash method. Briefly, 1-2 Â 10 6 cells were incubated with CD45-PC5, and additional relevant conjugated monoclonal antibodies (all antibodies from Beckman Coulter/Immunotech, Fullerton, CA, USA) at room temperature for 15 min protected from light. Red cell lysis was performed using the Beckman Coulter Immuno-Prep/Multi-Q Prep lysis system. Flow cytometric analysis was performed on a Beckman Coulter EPICS XL-MCL flow cytometer.
The lymphocyte gate was positioned using the CD45 v side scatter gating technique using the CD45-PC5 antibody that recognizes an epitope common to all CD45 isoforms. The CD5 þ /CD19 þ population was identified and gated for CD38 analysis. A 20% CD38 cutoff was used to define CD5/CD19/ CD38 positive/negative samples. 44 
Results
There is heterogeneity in the sensitivity of primary CLL cells to To measure the sensitivity of primary CLL cells to the BH3 mimetic ABT-737, peripheral blood samples were obtained from 30 patients with CLL. All patients had a peripheral blood lymphocyte count of 430 Â 10 9 /l. Eleven had relapsed, progressive disease at the time of sampling, with six having refractory disease after previous treatment with 4-6 different therapeutic regimens (see Supplementary Table 1 ). Eighteen were untreated at the time of sampling, with a median follow up of 4.5 years (range: 2-11 years) from diagnosis. Three subsequently required therapy for progressive disease. For one patient, the treatment history was unknown.
In all samples, in vitro incubation with ABT-737 induced apoptosis of CLL cells, but considerable inter-patient variability in sensitivity was observed (Figure 1a ). The samples were assigned into one of three subgroups (tertiles) based on the LC 50 to enable further investigation of the clinical and laboratory parameters associated with responsiveness to ABT-737. In 10 of the 30 samples, CLL cells were exquisitely sensitive, with an LC 50 o8 nM, and were arbitrarily assigned to a 'very sensitive' category. In 11 the LC 50 ranged between 8 and 50 nM (considered 'sensitive'), whereas 9 were considered 'more resistant' with LC 50 s of 450 nM, 8 of which had a LC 50 4100 nM.
A representative example from each of these three groups is shown in Figure 1b . The finding that the majority of primary CLL samples are sensitive to ABT-737 is consistent with earlier reports. 23, 26, 27, 45 However, we have shown that there is a significant variability (over 100-fold) in sensitivity among CLL samples, and that in particular, there are some patients with disease that is moderately resistant to this class of agent. Within that group, two patterns of dose-responsiveness were observed (Figure 1b, 3rd and 4th panels) . In seven of the nine samples, little cell death was observed until a threshold, and then near complete killing was attained at 1 mM. In two others (Figure 1b,  4th panel) , some cells were sensitive at relatively low concentrations, but the majority of cells were resistant even at the highest concentrations tested.
BCL2 family protein expression does not predict sensitivity to ABT-737
The importance of the relative expression of BCL2 family members in predicting sensitivity to BH3 mimetics such as ABT-737 has been demonstrated earlier, especially with regard to 
MCL1
. 25, 46 One potential explanation for the variability in sensitivity to ABT-737 between CLL samples would be the level of expression of these proteins. To examine this, lysates of primary CLL cells were analyzed by western blotting for the presence of the pro-survival proteins BCL2, BCLX L , BCL-W and MCL1, as well as the pro-apoptotic proteins BIM and BAX (Supplementary Figure 1) . In all the samples tested, BCLX L was present only in trace amounts or was undetectable, whereas almost all the samples had significant levels of BCL2. In this patient cohort, we could not discern any simple relationship between the sensitivity of a sample to ABT-737 and the expression of any of the proteins quantified (Figure 2a) .
Furthermore, when we examined the relative expression of BCL2 or MCL1 compared with BIM or BAX, there was no detectable relationship seen between the ratios of pro-survival to pro-apoptotic protein (Figure 2b ) and ABT-737 sensitivity. Hence, the expression patterns of BCL2 family proteins do not readily predict sensitivity to ABT-737 in the primary CLL cells investigated here.
Sensitivity to ABT-737 is independent of clinical prognostic factors
There is considerable variability in the natural history of CLL between patients. The commonly used determinants of prognosis include disease stage, patient age, cytogenetics (particularly presence of 17p deletions) and CD38 expressionFas a surrogate marker for IgVH mutational status. 1 We found that sensitivity of primary CLL cells to ABT-737 is independent of these factors, being as effective in samples with poor prognostic features as in those with good prognostic factors (Table 1) . Additionally, primary CLL cells showed similar variability in sensitivity to ABT-737 regardless of disease status (Table 1) .
Similarly, earlier exposure to cytotoxic agents did not predict for diminished sensitivity to ABT-737. Although some samples from patients with indolent disease that had never required treatment displayed moderate resistance to ABT-737 (max LC 50 1 mM), some of the most sensitive cells to ABT-737 in vitro were from patients who were treatment resistant (Table 1; Supplementary Table 1 ) and whose samples also showed resistance to multiple conventional cytotoxic agents in vitro (Table 1;  Supplementary Table 1 ). These studies suggest that ABT-737, or compounds of this class, may well be very useful for the treatment of CLL even where standard treatments have been ineffective.
Combination of ABT-737 and an anti-leukemic agent results in potent synergy in primary CLL cells
ABT-737 is a selective BH3 mimetic and hence is most likely to be effective if additional BCL2 pro-survival proteins such as MCL1 can be inactivated or neutralized. 25, 29 Potentially, a second agent, such as conventional chemotherapy drugs, could act in this regard. To examine this, formal synergy analyses were conducted with primary CLL cells treated in vitro with ABT-737 and a cytotoxic agent (dexamethasone, etoposide, F-ara-A or doxorubicin). After assessment of viability by propidium iodide exclusion, predicted response and synergy of the combination were calculated using the Bliss model of independence 35 and compared with the observed results.
When samples were very sensitive to the lowest doses of ABT-737, these analyses were not able to discern if synergy was In vitro response Sensitive to 42 cytotoxic agents 6 (32%) 6 (32%) 7 (36%) Resistant to 42 cytotoxic agents 3 (30%) 4 (40%) 3 (30%)
Where possible, known clinical prognostic markers (see Materials and methods), treatment history and in vitro response to cytotoxic drugs (dexamethasone, doxorubicin, F-Ara-A, etoposide) were compared with the response to ABT-737 in vitro. The samples were classed as sensitive to the standard cytotoxic agent tested provided the agent was able to kill more that 50% of the chronic lymphocytic leukemia sample (LC 50 ) at concentrations tested. Table 2 ) in 13 of 17 patient samples tested. This appeared independent of in vitro response to chemotherapy agents alone or earlier exposure to anti-leukemic therapy. Impressively, concomitant treatment with ABT-737 and a chemotherapy agent resulted in the majority of these 17 samples being sensitized to ABT-737, achieving an LC 50 of o8 nM in this setting ( Table 2) .
Discussion
The clinical management of CLL is in evolution, but a major hurdle is to identify agents likely to be effective in patients who have failed standard therapies. Like the other CLL cohorts that have been studied, 23, 26, 27, 45 most of the clinical samples studied here proved sensitive to ABT-737 in vitro (Figure 1a) . Of particular interest, we found that of six patients who were chemo-refractory, samples from five responded robustly to ABT-737 as a single agent (Table 1) . Furthermore, we found no correlation between responses to ABT-737 and responses to the other cytotoxic agents tested, presumably reflecting the unique mode of action of ABT-737. Taken together, these data suggest that the clinical testing of compounds of the same class as ABT-737 is desirable in this setting where there is an urgent and unmet need for improved therapies.
A major difference between our cohort and those reported earlier 23, 26, 27, 45 is the significant number of samples that are less sensitive to ABT-737 as a single agent (Figure 1a) . It is well recognized that multiple factors, both intrinsic and extrinsic (for example cytokines, use of stromal co-culture to resemble the in vivo microenvironment), influence responsiveness of CLL cells in culture. [47] [48] [49] We speculate that culturing CLL cells in primary patient serum or plasma, instead of fetal calf serum used by most other investigators, could account for the reduced sensitivity observed in some of the samples. Given the variable responses (with LC 50 values ranging over 100-fold), we were particularly interested in identifying which factor(s) that could account for the differences between samples because it is highly likely that clinical responses to compounds like ABT-737 will also be variable. Focusing on intrinsic factors, we examined whether expression of BCL2 family proteins determined sensitivity to ABT-737. However, in this cohort, we did not detect any obvious correlation between sensitivity to ABT-737 and expression of BCL2, MCL1, BAX or BIM, factors that others have reported to determine sensitivity to ABT-737 25, 26, 28, 29, 50, 51 ( Figure 2 ). Other recent studies have also shown that the levels of BCL2 proteins do not readily predict ABT-737 responsiveness in vitro in lymphoma, 52 CLL 53 or in chronic myeloid leukemia. 54 A potential explanation for this discrepancy is that other BCL2 family proteins not targeted by ABT-737, such as A1, 25, 53 may have a function, as may other factors more reflective of the complex nature of leukemic cells. It will be important to follow up these findings, especially in the context of evaluating clinical responses or when tumor resistance, either primary or acquired, is observed.
A rational approach to overcoming the relative resistance to ABT-737 is to combine it with other agents, especially ones with complementary modes of action. The unique molecular mechanism by which ABT-737 acts suggests that it should combine well with agents that primarily act to prime cells for apoptosis, such as DNA damaging agents, as we have recently shown in a mouse lymphoma model. 55 In this regard, we focused on combinations with known anti-leukemia agents because of their ready availability and recognized clinical profiles. We show that in combination with ABT-737, standard anti-CLL agents such as dexamethasone, and F-ara-A, as well as less commonly used agents such as etoposide and doxorubicin, act synergistically to increase cell killing ( Figure 3 ; Table 2 ). Thus, our studies complement and extend those that have studied the combination of ABT-737 with relatively novel agents such as proteasome inhibitors 45 or more molecularly targeted approaches such as Imatinib in chronic myeloid leukemia. 54 Our studies with CLL samples using ABT-737 are consistent with pre-clinical studies using an orally bioavailable BH3 mimetic compound in the same class, ABT-263. Using xenograft models, Tse et al. 31 found that ABT-263 enhanced the activity of chemotherapeutic agents in B-cell lymphoma, mantle cell lymphoma and myeloma. Clinical trials with ABT-263 as a single agent are in progress and it has shown substantial single agent therapeutic activity, particularly in CLL. 56, 57 These results and ours encourage the formal clinical testing of ABT-263 alone in CLL, and in combination with standard anti-leukemia agents in subsequent clinical trials.
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